ERBB2 and breast cancer: In BC, increased glycolytic activity, coupled with enhanced lactate production, has been linked to resistance to trastuzumab in HER2-positive BC, emphasizing the importance of targeting metabolic pathways in combination with traditional therapies to overcome resistance [80].